GlassScriptPhysician profile
Karen L Jimenez
NPI 1659395341
$2,981.55
in general payments reported to CMS, 2019-2025
28 companies · $860 in 2025
The $860 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $299 · 2021: $156 · 2022: $243 · 2023: $547 · 2024: $508 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,915.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $628.51 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $625.25 | 2019-2025 | Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $307.81 | 2023-2025 | |
| Lilly USA, LLC | $289.13 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $234.16 | 2021-2025 | |
| Pfizer INC. | $144.35 | 2020-2022 | |
| Glaxosmithkline, LLC. | $113.71 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $77.47 | 2023-2025 | Cologuard Collection Kit |
| Philips North America LLC | $55.28 | 2020-2025 | Mcot, (Ck4) Mcot |
| Phathom Pharmaceuticals, INC. | $48.95 | 2025 | Voquezna |
| Amgen INC. | $47.99 | 2023-2025 | Otezla, Repatha, Evenity |
| Merck Sharp & Dohme LLC | $45.75 | 2019 | |
| Currax Pharmaceuticals LLC | $42.35 | 2022 | |
| Esperion Therapeutics, INC. | $32.60 | 2020-2025 | Nexletol |
| Lundbeck LLC | $31.09 | 2025 | Rexulti |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $29.72 | 2025 | Injectafer |
| Allergan, INC. | $29.27 | 2020 | |
| Sk Life Science, INC. | $27.71 | 2023 | |
| Amarin Pharma, INC. | $23.88 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $20.34 | 2023 | Evkeeza |
| Dexcom, INC. | $18.68 | 2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $17.45 | 2023 | Quviviq |
| Insulet Corporation | $17.10 | 2023 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.31 | 2019 | |
| Xeris Pharmaceuticals, INC. | $15.28 | 2023 | Gvoke Hypopen |
| Becton, Dickinson and Company | $15.26 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.46 | 2024 | Xifaxan |
| Eisai INC. | $12.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Jimenez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.